Not enough data
Bill Alpert primarily covers investment analysis, with a significant focus on financial news and legal policy regulation. Based on his coverage attributes, he is likely to be receptive to pitches that provide in-depth investment analysis or cite relevant data from reputable sources.
Given the high percentage of coverage attributed to legal policy regulation, it's evident that Bill may also be interested in topics related to SEC regulations, compliance issues within the finance industry, or legal developments impacting investments.
He doesn't have a specific geographic focus but focuses mainly on the United States. Therefore, tailored pitches providing insights into US-based financial markets and regulatory changes would likely resonate well with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Bill Alpert
The presentation on Biogen’s experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects. Instead, Biogen stock is down 6%, to $197. Tuesday’s presentation on the drug diranersen, at London’s Alzheimer’s Association International Conference, left attendees confused about what to conclude from Biogen’s Phase 2 study known as CELIA.
It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.
By: Bill Alpert
It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.
Bill Alpert The U.S. Securities and Exchange Commission is turning the page on Wall Street documentation.
By: Bill Alpert
For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.
By: Bill Alpert
For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.
Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.
Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.
Its shares are up 30% since it raised $125 million in its initial public offering Friday.
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic.
